NEW YORK, Nov. 3, 2016 /PRNewswire/ -- July 2016 sees rises and falls in the market prices of major amino acids in China for various reasons. In particular, the price of lysine soars due to tight market supply. Meanwhile, some domestic threonine producers raised their quotations, affected by the environmental inspections this month. On the contrary, frequent floods reduce downstream demand for methionine and therefore, the market price of methionine falls slightly over last month.Thanks to the rises in the market prices, some amino acids improved their profitability. For instance, Yongan Pharmaceutical announced a large rise in its H1 2016 net profit, mainly due to the growth of both the sales volume and price of its taurine products. The leading taurine manufacturer may continue to raise prices in order to boost profits. In recent years, the company has expanded into the food and health care product industries.Yet, there are some amino acid enterprises facing great challenges. Star Lake Bioscience predicted to continue suffering losses in its H1 2016 financial pre-announcement and may delist if the losses continue in H2. Its API businesses which are of high gross profit margin may be its way out.Domestic market of amino acid derivatives develops stably. On 5 July, Zhenyuan Pharm announced its plan to expand SAM production capacity in the coming period. At present, there are only two domestic enterprises approved to sell SAM for injection. Given the large demand, the SAM market is promising.On 5 July, 2016, Zhenyuan Pharm announced its plan to expand SAM production capacity in the coming period. At present, there are merely two enterprises allowed to sell SAM for injection. However, given the large domestic demand, more pharmaceutical manufacturers have started to apply for production approval. So far, the Chinese SAM market has been in stable development.